Barclays raised the firm’s price target on Kymera Therapeutics (KYMR) to $70 from $60 and keeps an Overweight rating on the shares following the Q3 report. The firm cites increased optimism for KT-621 for the target bump.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Reports Q3 2025 Financial Results
- Kymera Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
- Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges
- Kymera Therapeutics price target raised to $73 from $70 at Morgan Stanley
- Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release